Annex Advisory Services LLC Grows Stake in LeMaitre Vascular, Inc. $LMAT

Key Points

• Annex Advisory Services LLC increased its stake in LeMaitre Vascular by 535.2% during the second quarter, now owning 219,667 shares valued at approximately $18.2 million.
• Analysts have set new price targets for LeMaitre Vascular, with Barrington Research and Cantor Fitzgerald both raising their target prices to $95.00, indicating a positive outlook for the stock.
• LeMaitre Vascular recently declared a quarterly dividend of $0.20 per share, translating to an annualized yield of 0.9% and a payout ratio of 38.83%.

Annex Advisory Services LLC raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 535.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 219,667 shares of the medical instruments supplier's stock after purchasing an additional 185,085 shares during the quarter. Annex Advisory Services LLC owned 0.97% of LeMaitre Vascular worth $18,243,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LMAT. Opal Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the first quarter valued at about $26,000. NBC Securities Inc. acquired a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $36,000. Geneos Wealth Management Inc. increased its holdings in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in LeMaitre Vascular in the 1st quarter valued at about $50,000. Finally, US Bancorp DE grew its holdings in LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 368 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Analysts Set New Price Targets

LMAT has been the topic of a number of analyst reports. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research report on Wednesday, August 6th. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of "Hold" and a consensus target price of $97.60.

Insider Activity at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares of the company's stock, valued at $269,875.80. The trade was a 69.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Stock Up 0.0%

Shares of LMAT traded up $0.04 on Monday, reaching $92.29. The company's stock had a trading volume of 171,259 shares, compared to its average volume of 190,511. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The stock has a market capitalization of $2.09 billion, a PE ratio of 44.80, a PEG ratio of 2.37 and a beta of 0.79. The firm has a fifty day moving average of $90.52 and a 200-day moving average of $85.97.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.LeMaitre Vascular's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.52 EPS. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is 38.83%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.